

# INTERIM REPORT Q1 2023

Webcast at 10:00 am CET – May 26, 2023



# Disclaimer

---

*This presentation, which should be understood to include these slides, their contents or any part of them, any oral presentation, any question or answer session and any written or oral materials discussed or distributed during a company presentation (the "Presentation"), has been prepared by Scandion Oncology A/S ("Scandion Oncology" or the "Company"), to be used solely for a company presentation. The information contained in the Presentation is provided solely for this purpose.*

*This Presentation does not constitute or form part of, and should not be construed as, any offer, invitation, solicitation or recommendation to purchase, sell or subscribe for any securities in any jurisdiction. The Presentation is intended to present background information on the Company, its business and the industry in which it operates and is not intended to provide complete disclosure. The Company has not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "Securities Act"), or under any of the relevant securities laws of any state or other jurisdiction of the United States of America.*

*Certain information contained herein has been obtained from published sources prepared by other parties that the Company has deemed to be relevant and trustworthy. No representation or warranty, express or implied, is made by the Company as to the accuracy, completeness or verification of any information contained in this Presentation. The Company has not made any independent review of information based on public statistics or information from an independent third party regarding the market information that has been provided by such third party, the industry or general publications.*

*Statements in this Presentation, including those regarding the possible or assumed future or other performance of the Company or its industry or other trend projections, constitute forward-looking statements. By their nature, forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors as they relate to events and depend on circumstances that will or may occur in the future, whether or not outside the control of the Company. No assurance is given that such forward-looking statements will prove to be correct. Past performance does not guarantee or predict future performance. Moreover, the Company does not – to the extent this is not required by law - undertake any obligation to review, update or confirm expectations or estimates or to release any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this Presentation.*


*This Presentation as well as any other information provided by or on behalf of the Company in connection herewith shall be governed by Danish law. The courts of Denmark, with the District Court of Copenhagen as the first instance, shall have exclusive jurisdiction to settle any conflict or dispute arising out of or in connection with this Presentation or related matters.*

# Agenda

---

- **Highlights from Q1 2023 and after**
- **AML progress**
- **Clinical trials & pipeline**
- **Financial update**
- **Strategic priorities & expected significant events 2023**
- **Core company strengths**

# Cancer drug resistance is causing up to 90% of cancer deaths



**Close to 10 million people are dying from cancer every year**

**Likely up to 90% of cancer deaths are due to drug resistant cancer cells<sup>1</sup>**

**40-50% of drugs in development fail due to lack of efficacy<sup>2</sup> – A big proportion of these failures are likely caused by undetected drug resistance**

# Highlights from Q1 2023 and after

---

**Executing on AML-strategy**

**PANTAX primary endpoint achieved**

**Progressing CORIST**



# AML represents an interesting opportunity...

---



## SCIENTIFIC RATIONALE


- High mortality, high unmet need
- Relapse/drug resistance major issue
- Resistance tied to ABCG2
- SCO-101 only ABCG2-inhibitor in clinical development



## STRATEGIC RATIONALE

- De-risking from R&D perspective
- Expands potential of SCO-101
- AML-market growth driven by relapse treatment
- Combination treatment of AML a significant commercial opportunity

# ... and we are executing our strategy



# PANTAX primary endpoint achieved

---

- Primary endpoint was achieved as the maximum tolerated dose of SCO-101 in combination with standard of care chemotherapies gemcitabine and nab-paclitaxel in patients with advanced pancreatic cancer was established at 200 milligrams given for 6 consecutive days every 2 weeks.
- Results support the overall profile of SCO-101 as well-tolerated in combination with different chemotherapies in vulnerable patients.
- Full analysis of all safety and efficacy outcomes expected to be performed late in 2023 with the final data presented in H1 2024.





# Developing first-in-class medicines for personalized therapy targeting cancer drug resistance

Program	Compound	Indication	Discovery / Pre-clinical	Phase I	Phase II	Phase III
CORIST	SCO-101	Colorectal cancer	SCO-101 + FOLFIRI		Part 3 interim results in H2, 2023	
PANTAX	SCO-101	Pancreatic cancer	SCO-101 + nab-paclitaxel and gemcitabine		Topline data in H1, 2023	
Hematology	SCO-101	AML	Pre-clinical data in H2, 2023			
201	SCO-201	Solid tumors	Currently on hold			

# Financial overview

# Financial Overview

- Net result and cost in line with expectations.
- Cash position sufficient to fund current activities into 2024.


Q1 interim report			
Financial summary DKK '000	Q1		Full year 2022
	2023	2022	
Other income	175	90	2,057
Research & development	-8,849	-13,122	-65,065
General & administration	-3,300	-3,280	-17,158
Financial items	66	-251	-2,034
Tax	2,620	3,644	5,500
<b>Net result</b>	<b>-9,288</b>	<b>-12,919</b>	<b>-76,700</b>
Earnings per share (DKK)	-0.23	-0.40	-1.88
<b>Cash position</b>	<b>60,185</b>	<b>87,965</b>	<b>77,605</b>

Financing of the Company's activities into 2024

# Cash Position



Operating Expenses 2021 - 2023



## Progression of expenses

As expected, we continue to see a decline in expenses as the effect of our cost reductions are incurred

# Our strategic priorities 2023/24 with multiple shots on goal...



**Continue CORIST and PANTAX  
and obtain read outs according  
to plan**



**Define next steps for both  
mCRC and pancreatic cancer**



**Plan and conduct pre-clinical  
activities in hematology/AML**

# ... and several expected events in 2023

H1 2023



**PANTAX**

Topline data from phase Ib

H2 2023



**CORIST**

Topline data from part 3

H2 2023



**Hematology/AML**

Pre-clinical data

Financing secured into **2024**

# Scandion Oncology core strengths

## We are one of the first movers in cancer drug resistance

- We are potentially first-in-class, targeting a huge market

## High medical need in an established market

- 10M cancer-related deaths annually
- SCO-101 has broad potential

## Solid financial position

- Current cash funds operations into 2024

## Strongly focused pipeline and clinical development

- Focused early-stage pipeline for value creation
- Opportunities to broaden into other cancer indications

## Run by seasoned leadership team

- Leadership team with a clear track record
- Best in class Clinical Advisory Board

## Multiple value inflection points over the next few years